Seasoned Public Company CFO With Financial and Cross Border Listing Experience to Join Management Team
Québec City, Québec – December 18, 2015 – TSO3 Inc. (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, has appointed Glen Kayll as Chief Financial Officer. Mr. Kayll succeeds Ms. Éléna Simard-Veilleux, who had been acting as interim CFO and has been appointed to the new position of vice president of finance.
Mr. Kayll brings to TSO3 more than 20 years of senior management experience, including as CFO and head of operations for both Canadian and U.S. public companies listed on the TSX and NASDAQ exchanges. He has lead large teams through significant corporate transactions, including more than $4 billion in mergers and acquisitions, financings and other transactions during his career.
Mr. Kayll was previously CFO of Argex Titanium, a TSX-traded, development-stage producer of high grade titanium dioxide (TiO2), which during his tenure secured a major partnership with the third largest chemical distributor in the world. Earlier he served as CFO and vice president of international operations for Coastal Contacts, a TSX and NASDAQ-listed, vertically integrated multinational manufacturer and internet retailer. Before Coastal, he was treasurer and head of investor relations at PMC-Sierra, a NASDAQ-listed, semiconductor and software solutions innovator which later became an S&P 500 component company.
“Glen’s appointment comes at an opportunistic time as significant milestones were recently achieved with our STERIZONE® VP4 Sterilizer in the United States and abroad,” said TSO3 president and CEO, R.M. (Ric) Rumble. “He brings a 20-year track record of increasing shareholder value in technology and manufacturing industries with significant operating and capital markets experience in high-growth multinational businesses. We expect to leverage his established relationships in the global financial and investment communities.”
“TSO3 is embarking on the next phase of its growth cycle with the commercial rollout of their revolutionary STERIZONE® VP4 Sterilizer,” said Mr. Kayll. “The recently announced exclusive global distribution agreement with Getinge Infection Control is validation of TSO3’s sterilization technology and also demonstrates Getinge’s substantial financial commitment over the next five years. The unique opportunity to be part of an organization that is improving the standard of patient care worldwide combines my personal interests with my professional experience and I look forward to joining the TSO3 team.”
Mr. Kayll holds a Bachelor of Commerce degree from Carleton University, an MBA from Simon Fraser University, and is a CPA.
Founded in 1998, TSO3’s activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. It also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes. For more information about TSO3, visit the company’s web site at www.tso3.com or contact Liolios Group at (949) 574-3860 or email TOS@liolios.com.
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
– 30 –Back to Posts